Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Coral Laboratories Ltd

Your Vote -

Buy

40.00%

Hold

20.00%

Sell

40.00%

40.00%

5 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Coral Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Coral Labs. Q2 net profit down 8.78% at Rs 5.82 cr

    14 Nov 2025, 9:31PM The company reported standalone net profit of Rs 5.82 crore for the quarter ended September 30, 2025 as compared to Rs 6.38 crore in the same period l
  • Coral Labs. - Results - Financial Results For Quarter And Half Year Ended September 30, 2025

    14 Nov 2025, 6:10PM The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended Sep
  • Coral Labs. - Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14, 2025, Pursuant To Regulation 30 (Re

    14 Nov 2025, 5:53PM The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended Sep
  • Coral Labs. - Board Meeting Intimation for Notice Under Regulation 29(1) Of The Securities And Exchange Board Of India (Listi

    7 Nov 2025, 4:40PM Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider a
  • Coral Labs. has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    17 Oct 2025, 11:40AM As of September 2025, 71.51% is owned by Promoters and 28.49% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 19.97% and
  • Coral Labs. - Outcome Of The Board Meeting Held On October 13, 2025 For Capacity Expansion At The Plant Located At Dehradun \

    13 Oct 2025, 4:34PM Subject: Outcome of the Board meeting held on October 13, 2025 for Capacity Expansion at the Plant located at Dehradun \r\n\r\nWith reference to the c
  • Coral Labs. - Intimation Regarding Capacity Addition Under Regulation 30 (Read With Part A Of Schedule III) Of The Securities

    13 Oct 2025, 3:52PM Intimation regarding Capacity addition under Regulation 30 (Read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing O
  • Coral Labs. - Board Meeting Outcome for Outcome Of The Board Meeting Held On October 13, 2025 For Capacity Expansion At The P

    13 Oct 2025, 3:37PM We are pleased to inform you that the Board of Directors of the Company in their meeting held on Monday, October 13, 2025, at the Registered Office of
  • Coral Labs. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Oct 2025, 2:53PM SUB: CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018\r\nPlease find attached herewith Certificate under R
  • Coral Labs. - Combined Scrutinizer Report For Remote E-Voting And Voting At The AGM Carried Out For The 43Rd Annual General M

    26 Sep 2025, 6:55PM Please find enclosed herewith Combined Scrutinizer Report for Remote e-voting and voting at the AGM carried out for the 43rd Annual General Meeting of
  • Coral Labs. - Shareholder Meeting / Postal Ballot-Outcome of AGM

    26 Sep 2025, 5:19PM Proceeding of 43rd Annual General Meeting of the Company held on Friday, September 26, 2025
  • Coral Labs. - Board Meeting Outcome for Outcome Of The Board Meeting Held On September 25, 2025, Pursuant To Regulation 30 (R

    25 Sep 2025, 2:19PM We are pleased to inform you that the Board of Directors of the Company in their meeting held on Thursday, September 25, 2025, at the Registered Offic
  • Coral Labs. - Board Meeting Intimation for Notice Under Regulattion 29(1) Of The Securities And Exchange Board Of India (List

    20 Sep 2025, 3:12PM Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2025 ,inter alia, to consider a
  • Coral Labs. - Notice Convening The 43Rd Annual General Meeting (AGM) And The Annual Report For Financial Year 2024-2025.

    3 Sep 2025, 4:05PM Copy of Notice Convening 43rd Annual General Meeting (AGM) of the Company will be held on Friday, 26 September, 2025 at 12:00 PM (IST) through Video C
  • Coral Labs. - Reg. 34 (1) Annual Report.

    3 Sep 2025, 3:58PM Subject: Notice convening the 43rd Annual General Meeting (AGM) and the Annual Report for Financial Year 2024-2025.\r\n\r\nDear Sir/ Ma'am,\r\n\r\nPur

Key fundamentals

Evaluate the intrinsic value of Coral Laboratories Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 204.7645 177.4966 154.7981 162.0922 142.8974
Liabilities 204.7645 177.4966 154.7981 162.0922 142.8974
Equity 3.5726 3.5726 3.5726 3.5726 3.5726
Gross Profit 26.2394 16.2389 3.8117 8.2142 15.8492
Net Profit 24.1556 15.789 6.4454 9.0457 13.5546
Cash From Operating Activities -1.2223 -5.4646 12.6652 6.0837 1.1169
NPM(%) 21 18.87 8.25 11.96 14.03
Revenue 115.0053 83.6605 78.1185 75.6107 96.5673
Expenses 88.7659 67.4216 74.3068 67.3965 80.7181
ROE(%) 11.86 7.75 3.16 4.44 6.65

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Coral Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 776.00 -1.65 0.00 283.93 301.39 0.64
Lotus Eye Hospital and Institute Ltd 105.05 0.19 328.13 1034.62 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 20.21 -0.05 0.00 2148.20 -39.50 0.00
Astec Lifesciences Ltd 888.85 7.47 0.00 975.67 -604.77 0.00

Company Info

Coral Laboratories P Ltd was incorporated on 19.6.1981 and was then converted into a Public Ltd company vide special resolution passed by the shareholders at the meeting held on 9th March 93. The company proposes to manufacture various pharmaceuticals formulations like tablets, capsules, dry syrups, liquieds and ointments and the company has not undertaken any commercial or business activity till date. The company has been promoted by Mr. N B Doshi, Chairman & Managing Director of the company. 2000 - Received WHO GMP Certificate for Baroda Plant. - Received ISO 9002 Certificate of Quality System Assessment issued by American Quality Assessors. 2001 - Entered in Global Marketing and started Exporting to Sri Lanka, Papua New Guinea, Cambodia and Kenya. - Renewal of WHO - GMP Certificate. 2002 - Entered into New Global Markets such as Ghana, Malawi, Nigeria, Lesotho, Ukraine and Vietnam. 2003 - Manufacturing Unit approved by (NAFDAC) Nigeria Food & Drug Administration. 2004 - Daman manufacturing unit started manufacturing since March 2004. This manufacturing unit is design to acquirer U.S. FDA & U.K. MHRA Certification. - Established a Quality Management System that is in compliance with the International Quality System Standard ISO 9001: 2008 Certificate Certificate No: IN015692. 2005 - Received WHO - GMP Certificate for Daman Plant. Manufacturing Unit No. 3 under construction at Dehradun. - Started Contract Manufacturing for ACI Pharm - USA and Medicale Pharmaceutique- France for their exports. - Recd ISO 9001-2008 Certificate for Daman plant. 2006 - Started Dehra Doon plant having facility to manufacture Tablets, Capsules, Liquids, Ointments, Lotion, Dry Syrup, Injectables(Dry Powder). 2009 - Received WHO GMP Certificate for Dehradun Plant. 2011 -Coral Laboratories Ltd has recommended dividend @ 15% i.e. Rs. 1.50 per Equity Shares of Rs. 10/-. 2012 -Coral Laboratories Ltd has recommended Dividend @ 15 % i.e. Rs. 1.50/-. per equity share of Rs. 10/- each. 2013 -Coral Laboratories Ltd has recommended Final Dividend @ 15 % i.e. Rs. 1.50/- per equity share of Rs. 10/- each 2014 -Coral Laboratories Ltd has recommended Dividend @ 20% i.e. Rs. 2/- per equity share of Rs. 10/- each.

Coral Laboratories P Ltd was incorporated on 19.6.1981 and was then converted into a Public Ltd company vide special resolution passed by the shareholders at the meeting held on 9th March 93. The company proposes to manufacture various pharmaceuticals formulations like tablets, capsules, dry syrups, liquieds and ointments and the company has not undertaken any commercial or business activity till date. The company has been promoted by Mr. N B Doshi, Chairman & Managing Director of the company. 2000 - Received WHO GMP Certificate for Baroda Plant. - Received ISO 9002 Certificate of Quality System Assessment issued by American Quality Assessors. 2001 - Entered in Global Marketing and started Exporting to Sri Lanka, Papua New Guinea, Cambodia and Kenya. - Renewal of WHO - GMP Certificate. 2002 - Entered into New Global Markets such as Ghana, Malawi, Nigeria, Lesotho, Ukraine and Vietnam. 2003 - Manufacturing Unit approved by (NAFDAC) Nigeria Food & Drug Administration. 2004 - Daman manufacturing unit started manufacturing since March 2004. This manufacturing unit is design to acquirer U.S. FDA & U.K. MHRA Certification. - Established a Quality Management System that is in compliance with the International Quality System Standard ISO 9001: 2008 Certificate Certificate No: IN015692. 2005 - Received WHO - GMP Certificate for Daman Plant. Manufacturing Unit No. 3 under construction at Dehradun. - Started Contract Manufacturing for ACI Pharm - USA and Medicale Pharmaceutique- France for their exports. - Recd ISO 9001-2008 Certificate for Daman plant. 2006 - Started Dehra Doon plant having facility to manufacture Tablets, Capsules, Liquids, Ointments, Lotion, Dry Syrup, Injectables(Dry Powder). 2009 - Received WHO GMP Certificate for Dehradun Plant. 2011 -Coral Laboratories Ltd has recommended dividend @ 15% i.e. Rs. 1.50 per Equity Shares of Rs. 10/-. 2012 -Coral Laboratories Ltd has recommended Dividend @ 15 % i.e. Rs. 1.50/-. per equity share of Rs. 10/- each. 2013 -Coral Laboratories Ltd has recommended Final Dividend @ 15 % i.e. Rs. 1.50/- per equity share of Rs. 10/- each 2014 -Coral Laboratories Ltd has recommended Dividend @ 20% i.e. Rs. 2/- per equity share of Rs. 10/- each.

Read More

Parent Organisation

Coral Laboratories Ltd.

Founded

06/02/1997

Managing Director

NSE Symbol

FAQ

The current price of Coral Laboratories Ltd is

The 52-week high for Coral Laboratories Ltd is

The market capitalization of Coral Laboratories Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Coral Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Coral Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Coral Laboratories Ltd shares.

The CEO of Coral Laboratories Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT